* Further bolstered Vermillion's intellectual property by advancing
the Company's license agreement with Stanford University to an
exclusive level. The license from Stanford covers the development
and commercialization of a biomarker panel used to assess the risk
* Hosted a roundtable teleconference focusing on Vermillion's PAD
diagnostic program and the need for improved detection of this
life- and limb-threatening condition. The teleconference featured
keynote speaker John Cooke, M.D., Ph.D., Professor of Medicine at
Stanford University, whose research forms the basis of Vermillion's
* Conducted market-development activities, including working with the
PAD Coalition and implementing an online physician survey to gather
market-based information, helping to define the Company's
commercialization strategy and broaden future clinical use of
-- Ovarian Cancer Diagnostic Program
* Continued to make progress with the clinical study evaluating OVA1
and plan to submit to the FDA in the second quarter.
* Presented data from several studies demonstrating the benefits of
the Company's ovarian cancer diagnostic test programs at the
Society of Gynecologic Oncologists' (SGO) 39th Annual Meeting on
Women's Cancer. The data suggest that use of Vermillion's tests
could help better identify women with early-stage ovarian cancer
and improve detection.
* Received the distinguished SGO Basic Science Poster Award for its
abstract, "Prospective independent validation of a marker panel for
distinguishing benign from malignant pelvic masses."
-- Hematology Diagnostic Program
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved